Recent Updates
Recently added Catalysts
AGEN Positive Sentiment

Armenien erteilt erste Marktzulassungen für BOT+BAL von Agenus bei zuvor behandeltem MSS-metastasiertem Kolorektalkarzinom

Thursday, October 8, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agenus Inc. has received market approvals from the Armenian Ministry of Health for its immuno-oncology treatments, Botvymo® (Botensilimab) and Evamplix® (Balstilimab). These drugs are approved for use in adult patients with MSS-metastatic colorectal cancer without active liver metastases. This approval represents a significant advancement for Agenus in the treatment landscape.

Market Sentiment Analysis

POSITIVE FACTORS

  • Armenia grants market approvals for Agenus' BOT and BAL.
  • The treatments are aimed at MSS-metastatic colorectal cancer.
  • This marks a significant milestone for Agenus in immuno-oncology.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+121%
120-day peak, hindsight
Typical move
3.1%
average across 3 past catalysts
Cash runway
~0 mo
High dilution risk
Lead asset
Botensilimab
Phase 2 · Early Rectal Cancer

Full Press Release Details

LEXINGTON, Massachusetts--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), ein führendes Unternehmen im Bereich der immunonkologischen Innovation, gab heute bekannt, dass das Gesundheitsministerium der Republik Armenien die Marktzulassungen für Botvymo® (Botensilimab, BOT) und Evamplix® (Balstilimab, BAL) erteilt hat. Die beiden Wirkstoffe wurden jeweils zur gemeinsamen Anwendung bei der Behandlung erwachsener Patienten mit MSS-metastasiertem Kolorektalkarzinom (mCRC) ohne aktive Lebermetastasen zu

Frequently Asked Questions

What drugs received approval in Armenia?

Botvymo® (Botensilimab) and Evamplix® (Balstilimab) received approval.

What condition are the drugs approved to treat?

They are approved for MSS-metastatic colorectal cancer.

Who issued the market approvals?

The approvals were granted by the Armenian Ministry of Health.

Are there any active liver metastases in approved patients?

The treatments are for patients without active liver metastases.

ShareAdd on Google
Tags: AGEN Agenus Botvymo Evamplix mCRC Armenia
Last updated: Oct 8, 2026

Biotech snapshot

Cash runway
$19M liquidity · $10M/mo burn
~0 mo
High dilution risk
Lead asset
BotensilimabPhase 2
Early Rectal Cancer →

Catalyst track record

+121%
best trade around AGEN's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for AGEN.

See every catalyst's timing & PoA →